03-08 67

ITW

Express Mail Label No. EV 326 985 504 US

Attorney Docket No. 59150-8037

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: NAGAIKE et al.

APPLICATION No.: 10/591,787

IA FILING DATE: March 3, 2005

FOR: RECOMBINANT VARICELLA-ZOSTER VIRUS

EXAMINER: To be Assigned

ART UNIT: 1642

CONF. No: 3253

Information Disclosure Statement Within Three Months of Application Filing or Before First Action – 37 C.F.R. § 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

\$_v •

MAR 0 6 2007

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an International Application or before the mailing date of a first Office Action on the merits or before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under 37 CFR §1.114, whichever occurs last (37 CFR 1.97(b)(4)). The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.704(d).

Respectfully submitted, Perkins Coie LLP

Date: Warch 6, 2007

Jacqueline F. Mahoney Registration No. 48,390

Correspondence Address:

Customer No. 22918
Perkins Coie LLP
P.O. Box 2168
Menlo Park, California 94026
(650) 838-4300

COMPLETE IF KNOWN Application Number 10/591,787 **INFORMATION DISCLOSURE** Confirmation Number 3253 **STATEMENT BY APPLICANT** Form PTO-1449 (Modified) MAR 06 2007 MAR 06 2007 March 3, 2005 Filing Date First Named Inventor Nagaike et al. Group Art Unit 1642 **Examiner Name** To be Assigned Sheet of 1 Attorney Docket No. 59150-8037

Cite No.		S. Patent or Appl	ication		Date of Publication or		
		BER	(if known)	Name of Patentee or Inventor of Cited Document	Filing Date of Cited Document	Pages, Columns, Line Where Relevant Passa or Relevant Figures App	ges
	<u>L</u>		FO	REIGN PATENT DOCUMENTS	<u> </u>		
Cite	Fore	eign Patent or Ap	Kind Code		Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	-
1.	EP	1 074 624	A	The Research Foundation for Microbial Diseases of Osaka University	2/7/01		
2.	EP	1 166 797	B	The Research Foundation for Microbial Diseases of Osaka University	1/2/02		
<u>-</u>		OTHER I	PRIOR AF	T-NON PATENT LITERATURE D	OCUMENTS		
Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.					_	
3.	Cohe	n <i>et al., PN.</i>	AS USA	<u>90</u> (15):7376-7380 (1993).	- Carrier	,	
	•						
					<u>s</u> .		
	lo. 1. 2.	ite lo. Office 1. EP ite (to)	Office NUMBER 1. EP 1 074 624 2. EP 1 166 797 OTHER I Include name (book, magazine, j	Office NUMBER (if known) 1. EP 1 074 624 A 2. EP 1 166 797 B1 OTHER PRIOR AR Include name of the author (book, magazine, journal, serial lo.	Name of Patentee or Applicant of Cited Document 1. EP 1 074 624 A1 The Research Foundation for Microbial Diseases of Osaka University 2. EP 1 166 797 B1 The Research Foundation for Microbial Diseases of Osaka University OTHER PRIOR ART-NON PATENT LITERATURE D Include name of the author (in CAPITAL LETTERS), title of the article (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), and/or country where published.	Name of Patentee or Applicant of Cited Document 1. EP 1 074 624 A1 The Research Foundation for Microbial Diseases of Osaka University 2. EP 1 166 797 B1 The Research Foundation for Microbial Diseases of Osaka University OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number and/or country where published.	Name of Patentee or Applicant of Cited Document Passages or Relevant Passages or Rele

EXAMINER		DATE CONSIDERED			
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).				